News & Updates

Bivalent HPV vaccine substantially reduces cervical cancer, CIN3 rates
Bivalent HPV vaccine substantially reduces cervical cancer, CIN3 rates
10 Feb 2022 byRoshini Claire Anthony

The risk of cervical cancer and grade 3 cervical intraepithelial neoplasia (CIN3) was substantially reduced among girls who were offered the bivalent human papillomavirus (HPV) vaccine, particularly those who were offered it at age 12–13 years, according to an observational study from England.

Bivalent HPV vaccine substantially reduces cervical cancer, CIN3 rates
10 Feb 2022